CD44 and acute myeloid leukemia: Compared to untreated cells, anti-CD44 reduced the adhesion of both BM- and PB-derived AML cells up to 4-fold with a mean of 1.3-fold (p < 0.001, n = 10) and 1.5-fold (p < 0.0001, n = 15), respectively (Figure 3d).